MA-SFM is an efficient and successful method of detecting RAPD

Article

Swinging flashlight test modified with magnification (MA-SFM) is an efficient way of detecting relative afferent papillary defect (RAPD).

Swinging flashlight test modified with magnification (MA-SFM) is an efficient way of detecting relative afferent papillary defect (RAPD), states an investigation in the Journal of Glaucoma.

Dr Parul Ichhpujani et al., Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India, performed a prospective, observational study of 101 consecutive patients. This study group consisted of 68 diagnosed glaucoma patients, 20 glaucoma suspects and 13 controls. All participants were screened for RAPD presence of absence. This was completed by using either the standard swinging flashlight method (S-SFM), MA-SFM or the ophthalmoscope swinging flashlight method.

Humphrey visual field mean deviation (MD) in each eye, intereye differences in MD, disc damage likelihood score (DDLS) and intereye differences in DDLS were all measured. Weighted κ scores were also recorded to ensure agreement between tests.

The most sensitive method for identifying RAPD is MA-SFM for both intereye differences in DDLS and MD. There was significant agreement between the tests for the MA-SFM method and moderate to significant agreement between the observers. The study suggests that using MA-SFM for detecting RAPD is a low-cost, simple and reproducible method.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.